Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156(suppl_1):S104-S114.
Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27:1578-1589.
Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis. 2004;63:1028-1034.
British Pain Society (BPS). Pain management during COVID-19 viral infection. Last reviewed March 26, 2020. Accessed October 19, 2020. https://www.britishpainsociety.org/static/uploads/resources/files/Pain_Management_during_COVID-19_viral_infection.pdf
Bruce E, Barlow-Pay F, Short R, et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med. 2020;9:2586.
Chang TS, Ding Y, Freund MK, et al. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System. Preprint. medRxiv. 2020;2020.07.03.20145581.
Clauw DJ, Häuser W, Cohen SP, et al. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain. 2020;161:1694-1697.
Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
Eccleston C, Blyth FM, Dear BF, et al. Managing patients with chronic pain during the COVID-19 outbreak: considerations for the rapid introduction of remotely supported (eHealth) pain management services. Pain. 2020;161:889-893.
European Medicines Agency (EMA). EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. Published March 18, 2020. Accessed October 19, 2020. https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19
Gianfrancesco M, Hyrich KL, Al-Adely S, et al; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859-866.
Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen). Drug Saf. 2013;36:135-144.
Ibuprofen 400 mg film-coated tablets (PL 16363/0523) [summary of product characteristics (SMPC)]. Last updated January 3, 2020. Accessed October 19, 2020. https://www.medicines.org.uk/emc/product/7020
Imam Z, Odish F, Armstrong J, et al. Independent correlates of hospitalization in 2040 patients with COVID-19 at a large hospital system in Michigan, United States. J Gen Intern Med. 2020;35:2516-2517.
Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288:469-476.
Jeong HE, Lee H, Shin HJ, et al. Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: a nationwide study. Clin Infect Dis. 2020. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1056/5876905 [Epub ahead of print]
Kragholm K, Gerds TA, Fosbøl E, et al. Association between prescribed ibuprofen and severe COVID-19 infection: a nationwide register-based cohort study. Clin Transl Sci. 2020. doi:10.1111/cts.12904 [Epub ahead of print]
Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79:851-858.
Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study. PLoS Med. 2020;17:e1003308.
Moore N, Carleton, B., Blin, P, et al. Does ibuprofen worsen COVID-19? Drug Saf. 2020;43:611-614.
Moore RA, Derry S, Aldington D, et al. Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;2015:CD008659.
Moore RA, Wiffen PJ, Derry S, et al. Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;2015:CD010794.
National Health Service (NHS). Healthy body: which painkiller? Last reviewed February 20, 2020. Accessed October 19, 2020. https://www.nhs.uk/live-well/healthy-body/which-painkiller-to-use/
National Health Service (NHS). NSAIDs. Last reviewed February 27, 2019. Accessed October 19, 2020. https://www.nhs.uk/conditions/nsaids/
Paracetamol tables 500 mg [summary of product characteristics (SMPC)]. Last updated April 2, 2020. Accessed October 19, 2020. https://www.medicines.org.uk/emc/product/5916/smpc#gref
Sbidian E, Penso L, Herlemont P, et al. [Long-term use of synthetic antimalarials and risk of occurrence of severe or fatal forms of COVID-19 Pharmacoepidemiology study from data from the National Health Data System (SNDS)]. EPI-PHARE. Published July 2, 2020. Accessed October 19, 2020. http://www.ameli.fr/fileadmin/user_upload/documents/Rapport_HCQ_covid_V11.pdf
Sodhi M. Safety of ibuprofen in patients with COVID-19. Chest. 2020;158:55-56.
Wong AYS, MacKenna B, Morton C, et al. OpenSAFELY: Do adults prescribed non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19? medRxiv. 2020.08.12.20171405.
World Health Organization (WHO). The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. Scientific brief. Published April 19, 2020. Accessed October 19, 2020. https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Nicholas Moore, MD, PhD

Emeritus Professor of Clinical Pharmacology
University of Bordeaux
Bordeaux, France

Disclosures

Disclosure: Nicholas Moore, MD, PhD, has disclosed no relevant financial relationships.

Bart Morlion, MD, PhD

Professor
University of Leuven
Leuven, Belgium
European Pain Federation EFIC
Brussels, Belgium

Disclosures

Disclosure: Bart Morlion, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Grünenthal; Pfizer Belgium; Reckitt Benckiser Group plc
Served as a speaker or a member of a speakers bureau for: Krka

Dot Lucas, BPharm (Hons)

Clinical Pharmacist
Ringmead Medical Practice
Bracknell, Berkshire, United Kingdom

Disclosures

Disclosure: Dot Lucas, BPharm (Hons), has disclosed no relevant financial relationships

Editors

Shanthi Voorn, PhD

Medical Education DirectorWebMD Global, LLC

Disclosures

Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Anita A Galdieri, PharmD, RPh

Senior Scientific Content Manager
WebMD Global, LLC

Disclosures

Disclosure: Anita A. Galdieri, PharmD, RPh, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

COVID-19 and NSAIDs: Misinformation in the Midst of a Pandemic

Authors: Nicholas Moore, MD, PhD; Bart Morlion, MD, PhD
CPD Released: 12/16/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 12/16/2021

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an audience of European primary care physicians, pediatricians, and pharmacists.

The goal of this activity is to educate clinicians on the safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in the setting of coronavirus disease 2019 (COVID-19).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Safety of NSAIDs in the setting of COVID-19
- Recommendations for NSAID therapy during the COVID-19 pandemic
Have greater competence related to
- Communicating best practices for NSAID use during the pandemic

Disclosures

Faculty

Nicholas Moore, MD, PhD

Emeritus Professor of Clinical Pharmacology
University of Bordeaux
Bordeaux, France

Disclosures

Disclosure: Nicholas Moore, MD, PhD, has disclosed no relevant financial relationships.

Bart Morlion, MD, PhD

Professor
University of Leuven
Leuven, Belgium
European Pain Federation EFIC
Brussels, Belgium

Disclosures

Disclosure: Bart Morlion, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Grünenthal; Pfizer Belgium; Reckitt Benckiser Group plc
Served as a speaker or a member of a speakers bureau for: Krka

Dot Lucas, BPharm (Hons)

Clinical Pharmacist
Ringmead Medical Practice
Bracknell, Berkshire, United Kingdom

Disclosures

Disclosure: Dot Lucas, BPharm (Hons), has disclosed no relevant financial relationships

Editors

Shanthi Voorn, PhD

Medical Education DirectorWebMD Global, LLC

Disclosures

Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Anita A Galdieri, PharmD, RPh

Senior Scientific Content Manager
WebMD Global, LLC

Disclosures

Disclosure: Anita A. Galdieri, PharmD, RPh, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

COVID-19 and NSAIDs: Misinformation in the Midst of a Pandemic

Authors: Nicholas Moore, MD, PhD; Bart Morlion, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 12/16/2020

Valid for credit through: 12/16/2021

processing....

Educational Impact Challenge

The goal of this activity is to educate clinicians on the safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in the setting of coronavirus disease 2019 (COVID-19).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CPD Information Download Slides

Communicating with patients about NSAIDs at the pharmacy

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Nicholas Moore, MD, PhD

Bart Morlion, MD, PhD

Dot Lucas, BPharm (Hons)

Editors

Shanthi Voorn, PhD

Anita A Galdieri, PharmD, RPh

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

COVID-19 and NSAIDs: Misinformation in the Midst of a Pandemic

Target Audience and Goal Statement

Disclosures

Faculty

Nicholas Moore, MD, PhD

Bart Morlion, MD, PhD

Dot Lucas, BPharm (Hons)

Editors

Shanthi Voorn, PhD

Anita A Galdieri, PharmD, RPh

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

COVID-19 and NSAIDs: Misinformation in the Midst of a Pandemic

Educational Impact Challenge